blank Quick help
blank Maintenance news

Misleading Register Alert event notification on 15.04.19

Following a clean-up exercise of event information regarding (previously) revoked patents, that were later reinstated, some existing revocation events ("Despatch of communication that patent is revoked") were duplicated on 15.04.2019.

2019.04.15

More...
blank News flashes

European Patent Register Assistant updated

In order to offer you the best possible learning experience we have launched an updated version of the European Patent Register Assistant online tutorial to include recent changes in the Register.

2019.08.29

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

About this file: EP3064509

EP3064509 - ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF OVARIAN CANCER [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  17.11.2017
Database last updated on 21.09.2019
FormerRequest for examination was made
Status updated on  15.06.2017
Most recent event   Tooltip11.08.2019New entry: Despatch of minutes of oral proceedings 
11.08.2019New entry: Despatch of communication that application is refused 
Applicant(s)For all designated states
F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel / CH
[2016/36]
Inventor(s)01 / Dupont, Jakob
c/o Genentech Inc.
1 DNA Way
South San Francisco, CA 94080 / US
02 / Irl, Cornelia
Grenzacherstrasse 124
4070 Basel / CH
 [2016/36]
Representative(s)Mewburn Ellis LLP
City Tower
40 Basinghall Street
London EC2V 5DE / GB
[N/P]
Former [2016/36]Brodbeck, Michel
F. Hoffmann-La Roche AG
Patent Department
Grenzacherstrasse 124
4070 Basel / CH
Application number, filing date16159080.722.02.2011
[2016/36]
Priority number, dateUS20100307095P23.02.2010         Original published format: US 307095 P
US20100351231P03.06.2010         Original published format: US 351231 P
US20100360059P30.06.2010         Original published format: US 360059 P
US201161439819P04.02.2011         Original published format: US 201161439819 P
[2016/36]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP3064509
Date:07.09.2016
Language:EN
[2016/36]
Type: A3 Search report 
No.:EP3064509
Date:02.11.2016
Language:EN
[2016/44]
Search report(s)(Supplementary) European search report - dispatched on:EP05.10.2016
ClassificationInternational:C07K16/22, A61K31/282, A61K31/337, A61K39/395
[2016/36]
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/01]
Former [2017/23]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Former [2016/36]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:ANTI-ANGIOGENESE-THERAPIE FÜR DIE BEHANDLUNG VON OVARIALKARZINOM[2016/36]
English:ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF OVARIAN CANCER[2016/36]
French:THÉRAPIE ANTI-ANGIOGENÈSE DESTINÉE AU TRAITEMENT DU CANCER DES OVAIRES[2016/36]
Examination procedure08.03.2016Date on which the examining division has become responsible
02.05.2017Examination requested  [2017/23]
21.06.2017Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
10.08.2017Amendment by applicant (claims and/or description)
15.11.2017Despatch of a communication from the examining division (Time limit: M04)
20.03.2018Reply to a communication from the examining division
11.05.2018Despatch of a communication from the examining division (Time limit: M04)
07.06.2018Reply to a communication from the examining division
20.06.2018Observations by third parties
06.07.2018Despatch of a communication from the examining division (Time limit: M04)
13.11.2018Reply to a communication from the examining division
17.06.2019Date of oral proceedings
12.08.2019Despatch of communication that the application is refused, reason: substantive examination {1}
12.08.2019Minutes of oral proceedings despatched
Parent application(s)   TooltipEP11706712.4  / EP2539367
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
10.08.2017Request for further processing filed
10.08.2017Full payment received (date of receipt of payment)
Request granted
23.08.2017Decision despatched
Fees paidRenewal fee
08.07.2016Renewal fee patent year 03
08.07.2016Renewal fee patent year 04
08.07.2016Renewal fee patent year 05
08.07.2016Renewal fee patent year 06
07.02.2017Renewal fee patent year 07
26.02.2018Renewal fee patent year 08
28.02.2019Renewal fee patent year 09
Documents cited:Search[A]  - HAN ERNEST S ET AL, "Bevacizumab in the treatment of ovarian cancer", EXPERT REVIEW OF ANTICANCER THERAPY, FUTURE DRUGS LTD, UK, (20071001), vol. 7, no. 10, ISSN 1744-8328, pages 1339 - 1345, XP009148910 [A] 1-6,8-14,16-18,20,22,23,28-41,44 * the whole document *

DOI:   http://dx.doi.org/10.1586/14737140.7.10.1339
 [I]  - FOSTER T ET AL, "A review of the current evidence for maintenance therapy in ovarian cancer", GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS, LONDON, GB, vol. 115, no. 2, doi:DOI:10.1016/J.YGYNO.2009.07.026, ISSN 0090-8258, (20091101), pages 290 - 301, (20090831), XP026683717 [I] 1-6,8-14,16-18,20,22,23,28-41,44 * the whole document * * see in particular table 2 *

DOI:   http://dx.doi.org/10.1016/j.ygyno.2009.07.026
 [A]  - PENSON RICHARD T ET AL, "Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 1 JAN 2010 LNKD- PUBMED:19917843, (20100101), vol. 28, no. 1, ISSN 1527-7755, pages 154 - 159, XP002639491 [A] 1-6,8-14,16-18,20,22,23,28-41,44 * the whole document *

DOI:   http://dx.doi.org/10.1200/JCO.2009.22.7900
 [A]  - ROSE PG ET AL, "Abstract No. 5546: Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.", J CLIN ONCOL, (2009), vol. 27, no. 15s, XP002639691 [A] 1-6,8-14,16-18,20,22,23,28-41,44 * the whole document *
 [XI]  - RICHARDSON D L ET AL, "Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer", GYNECOLOGIC ONCOLOGY, ACADEMIC PRESS, LONDON, GB, vol. 111, no. 3, doi:10.1016/J.YGYNO.2008.08.011, ISSN 0090-8258, (20081201), pages 461 - 466, (20080930), XP025691004 [X] 1-6,8,10-14,18,40 * the whole document * * see in particular abstract; page 462-465 * [I] 9,16,17,20,22,23,28-39,41,44

DOI:   http://dx.doi.org/10.1016/j.ygyno.2008.08.011
 [A]  - MABUCHI SEIJI ET AL, "Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 DEC 2008 LNKD- PUBMED:19047105, (20081201), vol. 14, no. 23, ISSN 1078-0432, pages 7781 - 7789, XP002639692 [A] 1-6,8-14,16-18,20,22,23,28-41,44 * the whole document *

DOI:   http://dx.doi.org/10.1158/1078-0432.CCR-08-0243
 [A]  - MCMEEKIN D D ET AL, "Abstract NO. 5540: Phase II study of intravenous (IV) bevacizumab and paclitaxel, and intraperitoneal (IP) cisplatin, followed by bevacizumab consolidation for advanced ovarian (O) or peritoneal (P) cancers.", J CLIN ONCOL, (2009), vol. 27, no. 15s, XP002639493 [A] 1-6,8-14,16-18,20,22,23,28-41,44 * the whole document *
 [XP]  - Roche Media Release, "Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer", (20110208), URL: http://www.roche.com/media/media_releases/med-cor-2011-02-08.htm, (20110530), XP002639498 [XP] 1-6,8-14,16-18,20,22,23,28-41,44 * the whole document *
 [T]  - F. TOMAO ET AL, "mprovement in Progression-FreeSurvival in OCEANS BevacizumabArm: A Critical Point of View", JOURNAL OF CLINICAL ONCOLOGY, US, (20121119), vol. 31, no. 1, doi:10.1200/JCO.2012.45.5717, ISSN 0732-183X, pages 165 - 166, XP055276887 [T] * the whole document *

DOI:   http://dx.doi.org/10.1200/JCO.2012.45.5717
 [T]  - C. AGHAJANIAN ET AL, "OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer", JOURNAL OF CLINICAL ONCOLOGY, US, (20120610), vol. 30, no. 17, doi:10.1200/JCO.2012.42.0505, ISSN 0732-183X, pages 2039 - 2045, XP055276885 [T] * the whole document *

DOI:   http://dx.doi.org/10.1200/JCO.2012.42.0505
 [T]  - AGHAJANIAN CAROL ET AL, "Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer", GYNECOLOGIC ONCOLOGY, (20150810), vol. 139, no. 1, doi:10.1016/J.YGYNO.2015.08.004, ISSN 0090-8258, pages 10 - 16, XP029282001 [T] * the whole document *

DOI:   http://dx.doi.org/10.1016/j.ygyno.2015.08.004
 [T]  - Anonymous, "A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma - Study Results - ClinicalTrials.gov", (20140926), URL: https://clinicaltrials.gov/ct2/show/results/NCT00434642?sect=X301256&view=results#evnt, (20160601), XP055277156 [T] * the whole document *
by applicantWO2005012359
 WO8906692
 US5500362
 WO9527062
 EP0404097
 WO9311161
 US5641870
 US4816567
 US5545807
 US5545806
 US5569825
 US5625126
 US5633425
 US5661016
 US5750373
 US2005186208
 US5739277
 WO0042072
 WO02060919
 US6884879
 US7060269
 US6582959
 US6703020
 US6054297
 WO9845332
 WO9630046
 WO9410202
 EP0666868
 US2006009360
 US2003206899
 US2003190317
 US2003203409
 US2005112126
 WO9744453
 US3773919
 US5565332
 US5573905
 US5567610
 US5229275
 US5730977
 WO9316185
 US2003157108
 US2004093621
 WO03011878
 US6602684
 WO9730087
 WO9858964
 WO9922764
 WO9951642
 US6194551
 US6242195
 US6528624
 US6538124
 US2005014934
 US2002004587
 WO9411026
 US4485045
 US4544545
 US5013556
    - MCGUIRE WP ET AL., "Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer", N ENG J MED, (1996), vol. 334, pages 1 - 6
    - PICCART MJ ET AL., "Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results", J NATL CANCER INST, vol. 92, pages 699 - 708
    - ALBERTS DS ET AL., "Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer", J CLIN ONCOL, (1992), vol. 10, pages 706 - 17
    - DU BOIS A ET AL., "A randomized clinical trial of cisplatinlpaclitaxel versus carboplatinlpaclitaxel as first-line treatment of ovarian cancer", J NATL CANCER INST, (20030903), vol. 95, no. 17, page 1320
    - OZOLS RF ET AL., "Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study", J CLIN ONCOL, (2003), vol. 21, pages 3194 - 200
    - SWENERTON K ET AL., "Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group", J CLIN ONCOL, (1992), vol. 10, pages 718 - 26
    - JEMAL A ET AL., "Cancer statistics", CA CANCER J CLIN, (2004), vol. 54, pages 8 - 29
    - FOLKMAN; KLAGSBRUN, SCIENCE, (1987), vol. 235, pages 442 - 447
    - HOLASH ET AL., SCIENCE, (1999), vol. 284, pages 1994 - 1998
    - GUERRIN ET AL., J. CELL PHYSIOL., (1995), vol. 164, pages 385 - 394
    - OBERG-WELSH ET AL., MOL. CELL. ENDOCRINOL., (1997), vol. 126, pages 125 - 132
    - SONDELL ET AL., J. NEUROSCI., (1999), vol. 19, pages 5731 - 5740
    - LEUNG ET AL., SCIENCE, (1989), vol. 246, page 1306
    - HOUCK ET AL., MOL. ENDOCRIN., (1991), vol. 5, page 1806
    - CHEN ET AL., J. MOL BIOL, (1999), vol. 293, pages 865 - 881
    - PRESTA ET AL., CANCER RES., (1997), vol. 57, pages 4593 - 4599
    - CHEN, Y. ET AL., J. MOL BIOL, (1999), vol. 293, pages 865 - 881
    - WARD ET AL., NATURE, (1989), vol. 341, pages 544 - 546
    - BIRD ET AL., SCIENCE, (1988), vol. 242, pages 423 - 426
    - HUSTON ET AL., PNAS (USA), (1988), vol. 85, pages 5879 - 5883
    - HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 6448
    - ZAPATA ET AL., PROTEIN ENG., (1995), vol. 8, no. 10, pages 1057 - 1062
    - KOHLER ET AL., NATURE, (1975), vol. 256, page 495
    - CLACKSON ET AL., NATURE, (1991), vol. 352, pages 624 - 628
    - MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, pages 581 - 597
    - CHOTHIA; LESK, J. MOL. BIOL., (1987), vol. 196, pages 901 - 917
    - PLUCKTHUN, The Pharmacology of Monoclonal Antibodies, SPRINGER-VERLAG, (1994), vol. 113, pages 269 - 315
    - MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, (1984), vol. 81, pages 6851 - 6855
    - JONES ET AL., NATURE, (1986), vol. 321, pages 522 - 525
    - RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 329
    - PRESTA, CURR. OP. STRUCT. BIOL., (1992), vol. 2, pages 593 - 596
    - VAUGHAN ET AL., NATURE BIOTECHNOLOGY, (1996), vol. 14, pages 309 - 314
    - SHEETS ET AL., PROC. NATL. ACAD. SCI., (1998), vol. 95, pages 6157 - 6162
    - HOOGENBOOM; WINTER, J. MOL. BIOL., (1991), vol. 227, page 381
    - MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, page 581
    - MARKS ET AL., BIO/TECHNOLOGY, (1992), vol. 10, pages 779 - 783
    - LONBERG ET AL., NATURE, (1994), vol. 368, pages 856 - 859
    - MORRISON, NATURE, (1994), vol. 368, pages 812 - 13
    - FISHWILD ET AL., NATURE BIOTECHNOLOGY, (1996), vol. 14, pages 845 - 51
    - NEUBERGER, NATURE BIOTECHNOLOGY, (1996), vol. 14, page 826
    - LONBERG; HUSZAR, INTERN. REV. IMMUNOL., (1995), vol. 13, pages 65 - 93
    - COLE ET AL., Monoclonal Antibodies and Cancer Therapy, ALAN R. LISS, (1985), page 77
    - BOERNER ET AL., J. IMMUNOL., (1991), vol. 147, no. 1, pages 86 - 95
    - BARBAS ET AL., PROC NAT. ACAD. SCI, USA, (1994), vol. 91, pages 3809 - 3813
    - SCHIER ET AL., GENE, (1995), vol. 169, pages 147 - 155
    - YELTON ET AL., J. IMMUNOL., (1995), vol. 155, pages 1994 - 2004
    - JACKSON ET AL., J. IMMUNOL., (1995), vol. 154, no. 7, pages 3310 - 9
    - HAWKINS ET AL., J. MOL. BIOL., (1992), vol. 226, pages 889 - 896
    - GHETIE ET AL., ANN. REV. IMMUNOL., (2000), vol. 18, pages 739 - 766
    - SHIELDS ET AL., J. BIOL. CHEM., (2001), vol. 276, pages 6591 - 6604
    - HINTON, J. BIOL. CHEM., (2004), vol. 279, pages 6213 - 6216
    - DENNIS ET AL., J. BIOL. CHEM., (2002), vol. 277, pages 35035 - 35043
    - KLAGSBRUN; D'AMORE, ANNU. REV. PHYSIOL., (1991), vol. 53, pages 217 - 39
    - STREIT; DETMAR, ONCOGENE, (2003), vol. 22, pages 3172 - 3179
    - FERRARA; ALITALO, NATURE MEDICINE, (1999), vol. 5, pages 1359 - 1364
    - TONINI ET AL., ONCOGENE, (2003), vol. 22, pages 6549 - 6556
    - SATO, INT. J. CLIN. ONCOL., (2003), vol. 8, pages 200 - 206
    - AGNEW, CHEM INTL. ED. ENGL., (1994), vol. 33, pages 183 - 186
    - "Cell cycle regulation, oncogenes, and antineoplastic drugs", MURAKAMI ET AL., The Molecular Basis of Cancer, WB SAUNDERS, (1995), page 13
    - WILMAN, "Prodrugs in Cancer Chemotherapy", BIOCHEMICAL SOCIETY TRANSACTIONS, vol. 14, pages 375 - 382
    - "Prodrugs: A Chemical Approach to Targeted Drug Delivery", STELLA ET AL., Directed Drug Delivery, HUMANA PRESS, (1985), pages 247 - 267
    - YONEDA J ET AL., "Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice", J NATL CANCER INST, (1998), vol. 90, doi:doi:10.1093/jnci/90.6.447, pages 447 - 54, XP055354375

DOI:   http://dx.doi.org/10.1093/jnci/90.6.447
    - NAKANISHI Y ET AL., "The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer", INT J GYNECOL PATHOL, (1997), vol. 16, pages 256 - 62
    - GASPARINI G ET AL., "Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas", INT J CANCER, (1996), vol. 69, pages 205 - 11
    - HOLLINGSWORTH HC ET AL., "Tumor angiogenesis in advanced stage ovarian carcinoma", AM J PATHOL, (1995), vol. 147, pages 33 - 41
    - PALEY PJ ET AL., "Vascular endothelial growth factor expression in early stage ovarian carcinoma", CANCER, (1997), vol. 80, doi:doi:10.1002/(SICI)1097-0142(19970701)80:1<98::AID-CNCR13>3.0.CO;2-A, pages 98 - 106, XP002231274

DOI:   http://dx.doi.org/10.1002/(SICI)1097-0142(19970701)80:1<98::AID-CNCR13>3.0.CO;2-A
    - ALVAREZ AA ET AL., "The prognostic significance of angiogenesis in epithelial ovarian carcinoma", CLIN CANCER RES, (1999), vol. 5, pages 587 - 91
    - GASPARINI G, "The rationale and future potential of angiogenesis inhibitors in neoplasia", DRUGS, (1999), vol. 58, doi:doi:10.2165/00003495-199958010-00003, pages 17 - 38, XP001002355

DOI:   http://dx.doi.org/10.2165/00003495-199958010-00003
    - VAN HINSBERGH VW ET AL., "Angiogenesis and anti-angiogenesis: perspectives for the treatment of solid tumors", ANN ONCOL 10 SU, (1999), vol. 14, pages 60 - 3
    - MALONNE H ET AL., "Mechanisms of tumor angiogenesis and therapeutic implications: angiogenesis inhibitors", CLIN EXP METASTASIS, (1999), vol. 17, doi:doi:10.1023/A:1026443925807, pages 1 - 14, XP000995006

DOI:   http://dx.doi.org/10.1023/A:1026443925807
    - FOLKMAN J, "Tumor angiogenesis: therapeutic implications", N ENG J MED, (1971), vol. 285, pages 1182 - 6, XP000884692
    - KIM KJ ET AL., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo", NATURE, (1993), vol. 362, doi:doi:10.1038/362841a0, pages 841 - 4, XP002018584

DOI:   http://dx.doi.org/10.1038/362841a0
    - LUO JC ET AL., "Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an anti vascular endothelial growth factorlpermeability factor neutralizing antibody", CANCER RES, (1998), vol. 58, pages 2594 - 600
    - FERRARA, LABORATORY INVESTIGATION, (1995), vol. 72, pages 615 - 618
    - OGAWA ET AL., J. BIOLOGICAL CHEM., (1998), vol. 273, pages 31273 - 31281
    - MEYER ET AL., EMBO J., (1999), vol. 18, pages 363 - 374
    - JOUKOV ET AL., EMBO. J., (1996), vol. 15, page 1751
    - LEE ET AL., PROC. NATL. ACAD. SCI. USA, (1996), vol. 93, pages 1988 - 1992
    - ACHEN ET AL., PROC. NATL. ACAD. SCI. USA, (1998), vol. 95, pages 548 - 553
    - JELTSCH ET AL., SCIENCE, (1997), vol. 276, pages 1423 - 1425
    - POPKOV ET AL., JOURNAL OF IMMUNOLOGICAL METHODS, (2004), vol. 288, pages 149 - 164
    - SHIBUYA ET AL., ONCOGENE, (1990), vol. 8, pages 519 - 527
    - DE VRIES ET AL., SCIENCE, (1992), vol. 255, pages 989 - 991
    - TERMAN ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., (1992), vol. 187, pages 1579 - 1586
    - SOKER ET AL., CELL, (1998), vol. 92, pages 735 - 45
    - YARDEN; ULLRICH, ANN. REV. BIOCHEM., (1988), vol. 57, pages 433 - 478
    - ULLRICH; SCHLESSINGER, CELL, (1990), vol. 61, pages 243 - 254
    - ULLRICH; SCHLESSINGER, CELL, (1990), vol. 61, pages 203 - 212
    - SCHLESSINGER; ULLRICH, NEURON, (1992), vol. 9, pages 1 - 20
    - MATTHEWS ET AL., PROC. NATL. ACAD. SCI. USA, (1991), vol. 88, pages 9026 - 9030
    - TERMAN ET AL., ONCOGENE, (1991), vol. 6, pages 1677 - 1683
    - ALVAREZ A ET AL., CLIN CANCER RES., (1999), vol. 5, pages 587 - 591
    - YAMAMOTO S ET AL., BR J CANCER, (1997), vol. 76, pages 1221 - 1227
    - GODING, Monoclonal Antibodies: Principles and Practice, ACADEMIC PRESS, (1986), pages 59 - 103
    - KOZBOR, J. IMMUNOL., (1984), vol. 133, page 3001
    - BRODEUR ET AL., Monoclonal Antibody Production Techniques and Applications, MARCEL DEKKER, INC., (1987), pages 51 - 63
    - MCCAFFERTY ET AL., NATURE, (1990), vol. 348, pages 552 - 554
    - WATERHOUSE ET AL., NUC. ACIDS. RES., (1993), vol. 21, pages 2265 - 2266
    - MORRISON ET AL., PROC. NATL ACAD. SCI. USA, (1984), vol. 81, page 6851
    - RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 327
    - VERHOEYEN ET AL., SCIENCE, (1988), vol. 239, pages 1534 - 1536
    - SIMS ET AL., J. IMMUNOL., (1993), vol. 151, page 2296
    - CHOTHIA ET AL., J. MOL. BIOL., (1987), vol. 196, page 901
    - CARTER ET AL., PROC. NATL. ACAD. SCI. USA, (1992), vol. 89, page 4285
    - PRESTA ET AL., J. IMMNOL., (1993), vol. 151, page 2623
    - JAKOBOVITS ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, page 2551
    - JAKOBOVITS ET AL., NATURE, (1993), vol. 362, pages 255 - 258
    - BRUGGERMANN ET AL., YEAR IN IMMUNO., (1993), vol. 7, page 33
    - DUCHOSAL ET AL., NATURE, (1992), vol. 355, page 258
    - MCCAFFERTY ET AL., NATURE, (1990), vol. 348, pages 552 - 553
    - JOHNSON; KEVIN S.; CHISWELL; DAVID J., CURRENT OPINION IN STRUCTURAL BIOLOGY, (1993), vol. 3, pages 564 - 571
    - GRIFFITH ET AL., EMBO J., (1993), vol. 12, pages 725 - 734
    - MORIMOTO ET AL., JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, (1992), vol. 24, pages 107 - 117
    - BRENNAN ET AL., SCIENCE, (1985), vol. 229, page 81
    - CARTER ET AL., BIO/TECHNOLOGY, (1992), vol. 10, pages 163 - 167
    - CUNNINGHAM; WELLS, SCIENCE, (1989), vol. 244, pages 1081 - 1085
    - A. L. LEHNINGER, Biochemistry, WORTH PUBLISHERS, (1975), pages 73 - 75
    - CARON ET AL., J. EXP MED., (1992), vol. 176, pages 1191 - 1195
    - SHOPES, B., J. IMMUNOL., (1992), vol. 148, pages 2918 - 2922
    - WOLFF ET AL., CANCER RESEARCH, (1993), vol. 53, pages 2560 - 2565
    - STEVENSON ET AL., ANTI-CANCER DRUG DESIGN, (1989), vol. 3, pages 219 - 230
    - VITETTA ET AL., SCIENCE, (1987), vol. 238, page 1098
    - EPSTEIN ET AL., PROC. NATL. ACAD. SCI. USA, (1985), vol. 82, page 3688
    - HWANG ET AL., PROC. NATL ACAD. SCI. USA, (1980), vol. 77, page 4030
    - MARTIN ET AL., J. BIOL. CHEM., (1982), vol. 257, pages 286 - 288
    - GABIZON ET AL., J. NATIONAL CANCER INST., (1989), vol. 81, no. 19, page 1484
    - PRESTA LG ET AL., "Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders", CANCER RES, (1997), vol. 57, pages 4593 - 9
    - BURGER RA ET AL., "Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study", J CLIN ONCOL, (2007), vol. 25, no. 33, doi:doi:10.1200/JCO.2007.11.5345, pages 5165 - 5171, XP055545111

DOI:   http://dx.doi.org/10.1200/JCO.2007.11.5345
    - CANNISTRA SA ET AL., "Phase II Study of Bevacizumab in Patients with Platinum Resistant Ovarian Cancer or Primary Peritoneal Serous Cancer", J CLIN ONCOL, (2007), vol. 25, no. 33, doi:doi:10.1200/JCO.2007.12.0782, pages 5180 - 86, XP055377324

DOI:   http://dx.doi.org/10.1200/JCO.2007.12.0782
    - THERASSE ET AL., J NATL. CANCER INST., (2000), vol. 92, pages 205 - 16
    - GINSBERG JM ET AL., "Use of single voided urine samples to estimate quantitative proteinuria", N ENGL J MED, (1983), vol. 309, pages 1543 - 6
    - RODBY RA ET AL., "The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy. The Collaborative Study Group", AM J KIDNEY DIS, (1995), vol. 26, pages 904 - 9
    - SCHWAB SJ ET AL., "Quantitation ofproteinuria by the use ofprotein-to-creatinine ratios in single urine samples", ARCH INTERN MED, (1987), vol. 147, pages 943 - 4
    - STEINHAUSLIN F; WAUTERS JP, "Quantitation of proteinuria in kidney transplant patients: accuracy of the urinary proteinlcreatinine ratio", CLIN NEPHROL, (1995), vol. 43, pages 110 - 5
    - WILSON DM; ANDERSON RL, "Protein-osmolality ratio for the quantitative assessment of proteinuria from a random urinalysis sample", AM J CLIN PATHOL, (1993), vol. 100, pages 419 - 24
    - ZELMANOVITZ T ET AL., "Proteinuria is still useful for the screening and diagnosis of overt diabetic nephropathy", DIABETES CARE, (1998), vol. 21, pages 1076 - 9
    - THERASSE P ET AL., "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada", J NATL CANCER INST, (2000), vol. 92, pages 205 - 16
    - BAST ET AL., N. ENGL. J. MED., (1983), vol. 309, page 88307
    - GUPPY ET AL., ONCOLOGISTS, (2002), vol. 7, page 437043
    - RUSTIN ET AL., J. CLIN. ONCOL., (2001), vol. 19, pages 4054 - 7
    - RUSTIN, J. CLIN. ONCOL., (2003), vol. 21, pages 187 - 93
    - RUSTIN ET AL., CLIN. CANCER RES., (2004), vol. 10, pages 3919 - 26
    - RUSTIN ET AL., J NATL. CANCER INST., (2004), vol. 96, pages 487 - 8
    - GYN ONCOL, (1990), vol. 38, page 373
    - GYN ONCOL, (1990), vol. 38, page 181
    - AMER J OB GYN, (1989), vol. 160, page 667
    - AMER J OB GVN, (1988), vol. 159, page 873
    - AMER J OB GVN, (1988), vol. 159, page 341
    - OB GVN, (1988), vol. 72, page 159
    - GYN ONCOL, (1990), vol. 36, page 299
    - PFISTERER; PLANTE M; VERGOTE I ET AL., "Gemcitabine plus Carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG", J. CLIN ONCOL, (2006), vol. 24, page 4699 707
    - YONEDA J; KUNIYASU H; CRISPENS MA ET AL., "Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice", J NATL CANCER INST., (19980318), vol. 90, page 447 54
    - THERASSE P; ARBUCK SG; EISENHAUSER EA ET AL., "New guidelines to evaluate the response to treatment in solid tumors", J NATL CANCER INST, (2000), vol. 92, pages 205 - 1
other   - MONK B.; COLEMAN R., "Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds", International Journal of Gynecological Cancer, (20091201), vol. 19, no. 2, pages S63 - S67, XP009506544

DOI:   http://dx.doi.org/10.1111/IGC.0b013e3181c104fa
    - Anonymous, "A Phase Ill, Multicenter, Randomized, Blinded, Placebo-Controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Platinum-Sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma", ClinicalTrials.gov archive / View of NCT00434642 on 2009_04_25/, (20090425), pages 1 - 3, URL: https://clinicaltrials.gov/archive/NCT00434642/2009_04_25, XP055493514